Revenio Group Corporation announced that in addition to diabetic retinopathy, the AI-aided iCare ILLUME screening is expanded to screen for age-related macular degeneration and glaucoma. The solution supports the early detection of these increasingly common eye diseases. The iCare ILLUME screening solution instantly detects the signs of sight-threatening diseases with artificial intelligence.

The solution, which has received excellent feedback from the markets, was introduced in the spring of 2022 to screen diabetic retinopathy. It can now screen for three common eye diseases: diabetic retinopathy, age- related macular degeneration, and glaucoma. Age-related eye diseases are becoming more common on a global level.

iCare ILLume screening solution helps detect eye diseases early, thus speeding up the start of treatment. The solution is easy to use, highly accurate, and fully automated. The severity of the eye disease can be seen on the screening report.

The screening solution has also been developed to be more flexible regarding the number and used fields of ophthalmic images The solution is now available in 11 languages. The iCare ILLume screening solutions supports clinical decision-making for ophthalmic diseases. The accurate data generated by iCare imaging devices and the related software are at the core of the solution.

iCare ILLUME combines the images taken with iCare DRSplus retinal imaging system with artificial intelligence, and a screening report is immediately available. After this, a digital referral for a follow-up examination by an ophthalmologist can be made for the patients who need it. This allows for even more extensive utilization of the high-quality images generated by retinal imaging devices to enhance the efficiency of treatment processes.

The comprehensive iCare Solutions includes digital tools to enhance and improve the quality of eye care while enabling the diagnosis and treatment of larger numbers of patients.